IDH1 mutations in grade II astrocytomas are associated with unfavorable progression‐free survival and prolonged postrecurrence survival

The favorable prognostic impact of mutations in the IDH1 gene is well documented for malignant gliomas; its influence on World Health Organization (WHO) grade II astrocytomas, however, is still under debate.

[1]  B. Christensen,et al.  DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. , 2011, Journal of the National Cancer Institute.

[2]  Jean-Yves Delattre,et al.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. , 2011, Neuro-oncology.

[3]  T. Haferlach,et al.  IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. , 2010, Blood.

[4]  Karsten Wrede,et al.  Molecular classification of low-grade diffuse gliomas. , 2010, The American journal of pathology.

[5]  R. Guillevin,et al.  IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas , 2010, Neurology.

[6]  C. Hoogenraad,et al.  Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.

[7]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[8]  E. Gottlieb,et al.  IDH1 mutations in gliomas: when an enzyme loses its grip. , 2010, Cancer cell.

[9]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[11]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[12]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[13]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[15]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[16]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[17]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[18]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[19]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[20]  M. Aghili,et al.  Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review , 2008, Journal of Neuro-Oncology.

[21]  G. Reifenberger,et al.  Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.

[22]  Jeen-Woo Park,et al.  Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase , 2007, Molecular and Cellular Biochemistry.

[23]  E. Struys.  D-2-Hydroxyglutaric aciduria: Unravelling the biochemical pathway and the genetic defect , 2006, Journal of Inherited Metabolic Disease.

[24]  A. Peraud,et al.  Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma , 2004, Cancer.

[25]  Y. Katayama,et al.  Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas , 2003, Brain pathology.

[26]  P. Kleihues,et al.  Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. Brada.  Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[28]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[29]  G. Semenza,et al.  Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .

[30]  R. Colman,et al.  Identification by Mutagenesis of Arginines in the Substrate Binding Site of the Porcine NADP-dependent Isocitrate Dehydrogenase* , 2000, The Journal of Biological Chemistry.

[31]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.

[32]  G. Jennings,et al.  Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase. , 1997, Biochemistry.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[34]  D. Karnofsky.  The clinical evaluation of chemotherapeutic agents in cancer , 1949 .

[35]  D.,et al.  Regression Models and Life-Tables , 2022 .